Rakuten Medical, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
11
Active:5
Completed:2
Trial Phases
3 Phases
Phase 1:5
Phase 2:2
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (50.0%)Phase 3
3 (30.0%)Phase 2
2 (20.0%)A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Phase 3
Recruiting
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Combination Product: ASP-1929 Photoimmunotherapy
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 412
- Registration Number
- NCT06699212
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇯🇵Hiroshima University, Hiroshima, Japan
🇯🇵Kyoto Prefectural University of Medicine, Kyoto, Japan
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
Phase 2
Terminated
- Conditions
- Head and Neck Cancer
- Interventions
- Combination Product: ASP-1929 Photoimmunotherapy
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05265013
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
Phase 1
Withdrawn
- Conditions
- Head and Neck Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Rakuten Medical, Inc.
- Registration Number
- NCT05220748
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
Phase 2
Active, not recruiting
- Conditions
- Head and Neck CancerSquamous Cell Carcinoma of Head and Neck
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05182866
- Locations
- 🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head-and-neck Squamous-cell CarcinomaLocally Advanced Cutaneous Squamous Cell CarcinomaMetastatic Cutaneous Squamous Cell Carcinoma
- Interventions
- Biological: 200 mg PembrolizumabBiological: 350 mg CemiplimabCombination Product: ASP-1929 PIT
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04305795
- Locations
- 🇺🇸
University of Miami Hospital and Clinics, Miami, Florida, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
- Prev
- 1
- 2
- Next
News
No news found